← Markets

Alcon Inc.

ALC · NYSE

Market closed$70.26$-0.360000 (-0.51%)After hours $68.85 · -2.01%

Key statistics

Previous close$70.62
Open$71.27
Day high$71.49
Day low$69.80
52-week high$92.55
52-week low$61.84
Market cap34.27B
Volume2.54M
Average volume2.18M
P/E ratio22.09
Forward P/E—
EPS3.18
Dividend yield+0.51%

Market context

Why it moved

ALC shares declined modestly amid broader healthcare sector pressure, as investor sentiment soured following concerns about slowing procedure growth in the medical device space highlighted by Intuitive Surgical's post-earnings selloff.

MarketbeatZacksKdnkFacebookBssnews

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Alcon closed modestly lower, holding up relatively well against broader medical device sector pressure triggered by Intuitive Surgical's warning that shifting insurance plan coverage could slow U.S. procedure volumes — a concern that dragged several medtech peers down sharply. Despite the sector headwind, Alcon remains in focus following its recently announced collaboration with RxSight to co-develop adjustable presbyopia-correcting IOLs, and analysts continue to highlight a robust pipeline including Unity VCS, PanOptix Pro, and Tryptyr. Consensus estimates point to 14% EPS growth and 7.3% revenue growth in 2026, with analysts citing fair value well above current levels.

-0.5098

July 17, 2026Alcon shares rose sharply, buoyed by a sector-wide healthcare rally following UnitedHealth Group's strong Q2 earnings beat and upward guidance revision, which lifted sentiment across medical device names. Adding company-specific momentum, Alcon announced a non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses — a pipeline catalyst analysts view as meaningful given Alcon's growing premium IOL franchise. Mizuho maintains an Outperform rating, though it trimmed its price target to $80, while Alcon's upcoming Q2 earnings (consensus at $2.77B in revenue, +7.3% YoY) remain a key near-term focus.

3.0949

July 16, 2026Alcon gained around 2.5% on above-average volume, rebounding from the prior session's 3.1% decline, as investors responded to a new collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lens technology and analyst coverage from Mizuho maintaining an Outperform rating. The stock was also highlighted alongside ISRG and IDXX as an AI-driven medical device laggard with strong momentum and improving earnings estimates poised for a second-half rebound, while consensus forecasts point to ~7.3% revenue growth and a modest earnings beat for the upcoming Q2 report.

2.4529

July 15, 2026Alcon Inc. fell nearly 3.1% in above-average volume — roughly 1.7x its typical daily turnover — as broader healthcare sector weakness weighed on medical device names, with peers like Abbott and Intuitive Surgical also declining sharply. The drop extended Alcon's year-to-date underperformance (-14% YTD), though some optimism is building around its recent RxSight collaboration to develop light-adjustable presbyopia-correcting IOLs ($60M upfront, up to $140M in milestones) and its positioning as an AI-driven medical device rebound candidate for 2H 2026, per Zacks. Shares edged back up ~0.86% in after-hours trading.

-3.1014

July 13, 2026Alcon shares rose nearly 2% during the regular session, buoyed by a high-profile product collaboration announcement: Alcon and RxSight agreed to jointly develop adjustable presbyopia-correcting intraocular lens (PCIOL) technology, combining Alcon's advanced optics with RxSight's post-surgery light-adjustment capabilities. The deal reinforces Alcon's strategy of expanding its surgical eye care portfolio through innovation partnerships, and comes as investors are broadly warming to medical device names ahead of Q2 earnings season. In after-hours trading, shares are pulling back modestly and holding near $68.83.

1.7549

July 9, 2026Alcon edged higher, benefiting from healthcare's continued sector momentum as analysts highlight a compelling valuation case. Wall Street's mean price target of ~$85 implies roughly 28% upside, with Zacks assigning a Buy rating after positive earnings estimate revisions. The recent collaboration with RxSight — a $60M upfront deal to co-develop adjustable presbyopia-correcting intraocular lenses, with up to $140M in milestones — remains in focus as a pipeline catalyst, while Argus maintained its Buy rating citing 10%-13% earnings growth guidance for 2026 and upcoming regulatory submissions in 2027-2028.

0.8714

July 8, 2026Alcon closed modestly lower as broad market risk-off sentiment — driven by Trump declaring the Iran peace MOU 'over,' sending oil surging 5%+ and triggering a global equity selloff — weighed on shares despite compelling company-specific catalysts. Investors are closely watching Alcon's recently announced $60M partnership with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses, a deal that positions Alcon at the forefront of next-gen cataract surgery innovation. Argus maintained a Buy rating with an $85 target, citing management's 10–13% earnings growth forecast for 2026 and a strong product pipeline with regulatory submissions expected in 2027–2028.

-0.4636

July 7, 2026Alcon closed down over 2% on elevated volume as investors weighed the strategic and financial implications of its newly announced $60 million upfront collaboration with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), with up to $140 million in additional milestone payments. While analysts see meaningful long-term upside — with a consensus price target near $95 implying roughly 40% upside from current levels — the near-term cash outlay and a premium valuation (P/E of ~41x) amid a broader healthcare sector earnings headwind appear to be weighing on sentiment.

-2.1367

The Globe and Mail · May 6, 2026Alcon (ALC) Q1 2026 Earnings Call TranscriptStock Titan · April 30, 2026Alcon shareholders approve CHF 0.28 dividend, add Scott HerrenBusiness Wire · March 16, 2026Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Benzinga · July 15, 2026Mizuho Maintains Outperform on Alcon, Lowers Price Target to $80
Mt Newswire · July 7, 2026Alcon Signs Joint Development, License Deal for Adjustable Lenses with RxSight
Mt Newswire · July 6, 2026Alcon, RxSight Launch Collaboration to Develop Adjustable Presbyopia-Correcting Lenses
Benzinga · July 6, 2026Alcon And RxSight Announce A Non-Exclusive Collaboration To Jointly Develop Adjustable Presbyopia-Correcting Intraocular Lenses
Benzinga · May 8, 2026Barclays Maintains Equal-Weight on Alcon, Lowers Price Target to $78
Benzinga · May 7, 2026Wells Fargo Maintains Overweight on Alcon, Lowers Price Target to $86
Benzinga · May 7, 2026Mizuho Maintains Outperform on Alcon, Lowers Price Target to $85
Mt Newswire · May 7, 2026Needham Trims Price Target on Alcon to $95 From $100, Keeps Buy Rating

Peers

S&P 500SPX · $7,457.69-1.01%Johnson & JohnsonJNJ · $253.04+1.23%The Cooper Companies, Inc.COO · $71.71-1.90%Bausch Health Companies Inc.BHC · $4.83-2.03%Bausch + Lomb CorporationBLCO · $16.26-3.27%Carl Zeiss Meditec AGCZMWF · $33.50-0.30%Align Technology, Inc.ALGN · $176.76-0.92%Solventum CorporationSOLV · $81.31-0.48%HOYA Corporation7741.T · ¥25,215.00+0.66%Coloplast A/SCOLO-B.CO · 422.80+2.13%STAAR Surgical CompanySTAA · $26.44-8.76%Glaukos CorporationGKOS · $156.83+0.93%